MASI - Masimo's Boost From Apple Litigation: Recent Market Victory May Not Last
2024-02-20 08:00:00 ET
Summary
- Masimo's favorable court ruling against Apple has boosted its shares and market share projections.
- In my view, the ongoing legal battle tarnishes Apple's image, while Masimo claims superiority in pulse oximetry technology.
- ActLight's DPD technology could potentially help Apple bypass Masimo's patents and create a superior device.
The favorable January 17th court ruling for Masimo Corporation ( MASI ) in its blood oxygen sensor IP battle with Apple Inc. ( AAPL ) has been a tailwind for MASI shares, which rose 12% since the ruling, and 2% on January 17th. The ruling effectively forced Apple to stop selling watches with oxygen measurement features in the U.S. until the appeals process of the ban is finally decided. In this article, we will discuss if Masimo has a sustainable advantage over Apple....
Masimo's Boost From Apple Litigation: Recent Market Victory May Not Last